GPC2 and neuroblastoma: In a different study, Bosse K. R. et al. have identified glypican-2 as a potential immunotherapeutic target for neuroblastoma due to its significantly higher expression in high-risk neuroblastomas, which was also associated with patient worse overall survival, and developed a highly cytotoxic antibody-drug conjugate that specifically targets glypican-2-expressing neuroblastoma cells (147).